BioAlberta Annual Achievement Awards streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Brass Dome Ventures Launches Brass Fund One to Spur Growth in the Alberta Business Ecosystem streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Date Time
Passion for mentorship drives successful serial entrepreneur’s new venture with University of Alberta
When Christopher Micetich attended the University of Alberta in the 1980s, he figured he would be a natural fit in chemistry.
After all, in 1980 his father Ronald Micetich, a world-renowned medicinal chemist, joined the Faculty of Pharmacy and Pharmaceutical Sciences as an adjunct professor teaching and working on contract chemical synthesis that would eventually lead to the creation of Ronald’s joint venture company with a major Japanese company.
That company, SynPhar Laboratories, would eventually file more than 100 compositional matter patents, one of which tazobactam, a beta lactamase inhibitor used in combination with antibiotics to increase their effectiveness would go on to have annual sales of more than $1 billion.
Date Time
Share
University of Alberta and Brass Dome Ventures Ltd. launch imYEG accelerator to increase commercialization of research-driven
The University of Alberta and a local business consultancy firm, with the backing of the federal government, have launched a new accelerator program specifically designed to increase the number and quality of commercial ventures at the earliest stages coming out of the university.
Innovation Masterminds Edmonton (imYEG) stems from a partnership between the U of A and Brass Dome Ventures Ltd., led by serial entrepreneur and U of A alumnus Christopher Micetich, to create an industry-led accelerator to address and overcome the earliest barriers faced by researchers just starting on the path to commercialization.